Results
ataxia
All 20 trial participants completed the questionnaire. If allocated to the active treatment arm, 75% of patients expected short‐term health benefits and 55% thought they would still have less severe ataxia at 1‐year follow‐up compared with baseline. After 2 weeks, an average reduction in ataxia severity of 31.5% (standard deviation, 22.2%) was anticipated. Conversely, 65% associated a lack of improvement with probable or definite allocation to the placebo group. High expectations of benefit were neither related to the type of intervention nor to clinical or demographic characteristics.